Sarepta Obtains Broader DMD Label For Elevidys

The gene therapy is now approved for all ambulatory boys with Duchenne muscular dystrophy ages 4 and older. The revised label also includes accelerated approval for non-ambulatory patients.

Expanded
Expanded label for Elevidys covers all ambulatory DMD patients 4 and older • Source: Shutterstock

Sarepta Therapeutics, Inc. obtained expanded US Food and Drug Administration approval of its Duchenne muscular dystrophy gene therapy Elevidys in ambulatory boys aged 4 and older, overcoming concerns after a confirmatory trial missed its primary endpoint last October. The 20 June FDA decision, which built on the June 2023 accelerated approval that cleared the drug for ambulatory boys aged 4-5, also provides a new accelerated approval for Elevidys to treat non-ambulatory boys ages 4 and older.

In announcing the label expansion by both age and ambulatory status, the FDA’s Center for Biologics Evaluation and Research said...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from New Products

More from Scrip

Rocket Comes Back To Earth With Restructuring Plan

 

The biotech will lay off nearly one-third of its workforce and focus on its cardiovascular gene therapy programs.

AZ Poised To Bring Self-Administered C5 Inhibitor To Market

 

Gefurulimab will give AstraZeneca a new option to compete against Argenx’s Vyvgart Hytrulo, which is available subcutaneously.

Roche Keen To Cut Out The Middle Men On US Pricing

 
• By 

The Swiss giant has been talking to the US government about selling medicines directly to patients.